Intranasal Ketamine for Anxiolysis in Pediatric Emergency Department Patients
Status:
Suspended
Trial end date:
2022-07-01
Target enrollment:
Participant gender:
Summary
Investigators plan to conduct a randomized, double-blinded, controlled study among pediatric
patients requiring minor procedures in the Emergency Department setting. Patients will be
randomized to one of two arms of intranasal treatments: ketamine 1.0 mg/kg (K) or midazolam
0.3 mg/kg (M). The primary outcome will be change in anxiety using the Modified Yale
Preoperative Anxiety Scale (mYPAS).